News

Men who have asymptomatic subclinical vascular disease are more likely to develop erectile dysfunction than men who don’t have early stage vascular disease, according to research presented at the...

NHLBI, Losartan, Marfan syndrome, atenolol

A National Institutes of Health-funded study comparing treatment with widely used blood pressure medications, atenolol or losartan, in patients with Marfan syndrome who had an enlarged aortic root...

stents, Cobra, celonova

CeloNova BioSciences, Inc., announced that positive first-in-man (FIM) clinical trial results found its Cobra PzF coronary stent system with an advanced nano-thin coating of Polyzene-F polymer to...

Men who have asymptomatic subclinical vascular disease are more likely to develop erectile dysfunction than men who don’t have early-stage vascular disease, according to research presented at the...

AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Long-term overtreatment with the anti-clotting drug warfarin combined with antiplatelet therapy to prevent stroke may raise the risk of dementia in people with atrial fibrillation.

AFIB, BMI, Loyola University Medical Center, Epicardial Adipose Tissue

Obesity is commonly measured as a person’s body mass index (BMI), but a Loyola University Medical Center study has found that the layer of fat around the outside of the heart is more closely...

A coordinated emergency response by healthcare teams to treat heart attack patients meant faster care that was associated with improved survival, according to research presented at the American...

Oxford clinical study, American Heart Association, abdominal aortic aneurism

Oxford University researchers presented data that reveal the extent to which smoking causes silent but deadly damage to health at the annual scientific meeting of the American Heart Association (...

heart valve repair, Moderate Ischemic Mitral Regurgitation, NHLB

Routinely adding mitral valve repair to coronary artery bypass graft surgery for heart attack...

DAPT study

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to...

Everflex, Iliac Study,Vascular Interventional Advances Conference

Covidien plc (NYSE: COV) announced results of the durability Iliac study and addition of the iliac indication for its EverFlex stent at the Vascular Interventional Advances (VIVA) 2014 conference...

Aortic Aneurysm, stent graft, Gore Excluder

Pierre Galvagni Silveira, M.D., Ph.D. enrolled the first two patients in the Gore Thoracoabdominal Aortic Aneurysm Clinical Study. This initial feasibility study of the Gore Excluder...

VIVA Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announced late-breaking clinical trial results VIVA 14, an annual multidisciplinary...

Covidien releases 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy ...

ClearFlow Inc. announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial (PRO-ACT), a clinical study evaluating the...

Five-year results from the largest and longest-running clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) confirmed long-term patency for patients treated...

VIVA, VIVA Physicians, Peripheral, Carotid Artery Device, clinical trial results

Viva Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announce clinical trial results and other new happenings at Viva '14, hosted in Las Vegas,...

For the treatment of peripheral artery disease in leg arteries above the knee, the IN.PACT Admiral ...

Future prevention and treatment strategies for vascular diseases may lie in the evaluation of early brain imaging tests long before heart attacks or strokes occur, according to a systematic review...

atrial fibrillation, FDA, Dual Epicardial and Endocardial Procedure, DEEP

Enrollment is open for the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial following U.S Food and Drug Administration Approval (FDA).